BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30064973)

  • 1. Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis.
    Pronier E; Bowman RL; Ahn J; Glass J; Kandoth C; Merlinsky TR; Whitfield JT; Durham BH; Gruet A; Hanasoge Somasundara AV; Rampal R; Melnick A; Koche RP; Taylor BS; Levine RL
    Blood; 2018 Sep; 132(12):1265-1278. PubMed ID: 30064973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
    Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
    Elife; 2016 Nov; 5():. PubMed ID: 27879203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.
    Poitras JL; Heiser D; Li L; Nguyen B; Nagai K; Duffield AS; Gamper C; Small D
    Oncotarget; 2016 Oct; 7(43):69124-69135. PubMed ID: 27636998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
    Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
    Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knock-in of the
    Annesley CE; Rabik C; Duffield AS; Rau RE; Magoon D; Li L; Huff V; Small D; Loeb DM; Brown P
    Oncotarget; 2018 Oct; 9(82):35313-35326. PubMed ID: 30450160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
    Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukemogenic potency of the novel FLT3-N676K mutant.
    Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
    Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia.
    Awada H; Durmaz A; Gurnari C; Kishtagari A; Zawit M; Pagliuca S; Visconte V
    Blood Cells Mol Dis; 2021 May; 88():102549. PubMed ID: 33636567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m
    Weng H; Huang H; Wu H; Qin X; Zhao BS; Dong L; Shi H; Skibbe J; Shen C; Hu C; Sheng Y; Wang Y; Wunderlich M; Zhang B; Dore LC; Su R; Deng X; Ferchen K; Li C; Sun M; Lu Z; Jiang X; Marcucci G; Mulloy JC; Yang J; Qian Z; Wei M; He C; Chen J
    Cell Stem Cell; 2018 Feb; 22(2):191-205.e9. PubMed ID: 29290617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
    Miglino M; Colombo N; Pica G; Grasso R; Clavio M; Bergamaschi M; Ballerini F; Ghiso A; Ghiggi C; Mitscheunig L; Beltrami G; Cagnetta A; Vignolo L; Lucchetti MV; Aquino S; Pierri I; Sessarego M; Carella AM; Gobbi M
    Leuk Lymphoma; 2011 Oct; 52(10):1961-9. PubMed ID: 21942328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of mutations in the cohesin complex in acute myeloid leukemia.
    Mazumdar C; Majeti R
    Int J Hematol; 2017 Jan; 105(1):31-36. PubMed ID: 27796738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.
    Lyu Y; Lou J; Yang Y; Feng J; Hao Y; Huang S; Yin L; Xu J; Huang D; Ma B; Zou D; Wang Y; Zhang Y; Zhang B; Chen P; Yu K; Lam EW; Wang X; Liu Q; Yan J; Jin B
    Leukemia; 2017 Dec; 31(12):2543-2551. PubMed ID: 28400619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear factor of activated T-cells, NFATC1, governs FLT3
    Solovey M; Wang Y; Michel C; Metzeler KH; Herold T; Göthert JR; Ellenrieder V; Hessmann E; Gattenlöhner S; Neubauer A; Pavlinic D; Benes V; Rupp O; Burchert A
    J Hematol Oncol; 2019 Jul; 12(1):72. PubMed ID: 31286998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wilms' tumor protein and FLT3-internal tandem duplication expression in patients with de novo acute myeloid leukemia.
    Spassov BV; Stoimenov AS; Balatzenko GN; Genova ML; Peichev DB; Konstantinov SM
    Hematology; 2011 Jan; 16(1):37-42. PubMed ID: 21269566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations.
    Merdin A; Dal MS; Çakar MK; Yildiz J; Ulu BU; Batgi H; Tetik A; Seçilmiş S; Darçin T; Şahin D; Bakirtaş M; Başçi S; Yiğenoğlu TN; Baysal NA; İskender D; Altuntaş F
    Medicine (Baltimore); 2020 Apr; 99(14):e19627. PubMed ID: 32243389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis.
    Hosen N; Shirakata T; Nishida S; Yanagihara M; Tsuboi A; Kawakami M; Oji Y; Oka Y; Okabe M; Tan B; Sugiyama H; Weissman IL
    Leukemia; 2007 Aug; 21(8):1783-91. PubMed ID: 17525726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker?
    De Marchi F; Candoni A; Zannier ME; Haley L; Lau BW; Fanin R
    Am J Hematol; 2017 May; 92(5):E72-E74. PubMed ID: 28211167
    [No Abstract]   [Full Text] [Related]  

  • 20. [THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].
    Goryainova NV
    Lik Sprava; 2014 Dec; (12):10-8. PubMed ID: 26638462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.